| Abstrakt: |
A recent report published by researchers from F. Hoffmann-La Roche Ltd. explores the impact of breast cancer diagnosis and treatment on government accounts, excluding health costs. The study focuses on HER2-positive early breast cancer (eBC) and its influence on labor market activity, taxes paid, and benefits received. The research suggests that women diagnosed with HER2-positive eBC may pay less in lifetime gross taxes and receive more in sickness benefits compared to healthy women. Treatments that improve outcomes are likely to result in fiscal gains for governments through increased workforce participation. [Extracted from the article] |
